[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519235":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":54,"collaborators":58,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":25,"eligibilityCriteria":67,"healthyVolunteers":64,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":25,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Chung Shan Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Coenzyme Q10","EXPERIMENTAL","Coenzyme Q10 300 mg\u002Fday (150 mg\u002Fb.i.d.)",[13],"Dietary Supplement: Coenzyme Q10",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo (dextrin)",[19],"Other: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","300 mg\u002Fday (150mg\u002Fb.i.d)",[9],null,{"type":6,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Starch, dextrin",[15],[30],{"name":31,"affiliation":5,"role":32},"Ping-Ting Lin, Ph.D.","STUDY_DIRECTOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":37,"email":38},"CONTACT","+886-4-24730022","12187","apt810@csmu.edu.tw",[40],{"facility":41,"status":42,"city":43,"state":25,"zip":25,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Chung Shan Medical University Hospital","RECRUITING","Taichung","Taiwan","TW",{"type":47,"coordinates":48},"Point",[49,50],120.6839,24.1469,{"lat":50,"lon":49},[53],{"name":31,"role":35,"phone":36,"phoneExt":37,"email":38},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Ping-Ting Lin","Professor",[59],{"name":60,"class":61},"National Science and Technology Council","FED","100519235","causal-effect-of-coenzyme-q10-nutrition-and-cognitive-dysfunction-in-the-metabolic-storm-hyperglycemia-and-sarcopenia-and-brain-derived-neurotrophic-factor-100519235",false,"NCT06040905","Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor","Inclusion Criteria:\n\n* Clinical diagnosis of mild cognitive impairment (MCI).\n* Clinical diagnosis of Alzheimer's Disease.\n* MCI and AD patients with hyperglycemia ( Fasting glucose \\>=100 mg\u002FdL).\n* MCI and AD patients with pre-sarcopenia (low calf circumference, low hand grip, or low muscle endurance).\n* Must be able to swallow tablets.\n\nExclusion Criteria:\n\n* Cancer patients.\n* Severe heart, lung, liver, and kidney diseases.\n* Severe disability or aphasia.\n* Malnutrition (body weight changes \\> 5% within one month).\n* Using coenzyme Q10 supplements.\n* Warfarin therapy.","ALL","50 Years","80 Years",{"count":72,"type":73},100,"ESTIMATED","INTERVENTIONAL",[76],"NA","The aim of the study is to investigate the effect of coenzyme Q10 supplementation (150 mg\u002Fb.i.d, 300 mg\u002Fd, 12 weeks) on coenzyme Q10, glucose parameters, BDNF, myokines, and cognitive function in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients who combined with hyperglycemia but without sarcopenia, or with hyperglycemia and pre-sarcopenia.",[79,80,81,82],"Mild Cognitive Impairment","Alzheimer Disease","Hyperglycemia","Pre-sarcopenia","2024-02-05",{"date":85,"type":86},"2024-02-07","ACTUAL",{"date":88,"type":86},"2023-12-26",{"date":90,"type":73},"2026-07-31",{"name":5,"class":6},1]